Our study also confirmed that Survivin was highly expressed in osteosarcoma-resistant cells, and overexpression of miR-506-3p or silencing of STAT3 was able to inhibit Survivin expression, thereby enhancing the sensitivity of drug-resistant osteosarcoma cells to doxorubicin. This evidence concerns the gene BIRC5 and osteosarcoma.